focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,788.50
Bid: 1,788.50
Ask: 1,789.00
Change: 32.50 (1.85%)
Spread: 0.50 (0.028%)
Open: 1,743.50
High: 1,792.50
Low: 1,740.50
Prev. Close: 1,756.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK BROKER RATINGS: Goldman Sachs Says Buy Royal Mail And Intertek

Fri, 07th Nov 2014 09:42

LONDON (Alliance News) - The following UK shares received analyst recommendations Friday morning and Thursday afternoon:
----------
FTSE 100
----------
GOLDMAN RAISES BABCOCK INTERNATIONAL PRICE TARGET TO 1438 (1380) PENCE - 'BUY'
----------
GOLDMAN RESUMES ROYAL MAIL WITH 'BUY' - TARGET 575 PENCE
----------
GOLDMAN RAISES INTERTEK TO 'BUY' ('NEUTRAL') - TARGET 3440 (3240) PENCE
----------
GOLDMAN RAISES EXPERIAN TO 'NEUTRAL' ('SELL') - TARGET 1078 (985) PENCE
----------
TRADERS: NOMURA RAISES EXPERIAN PRICE TARGET TO 1,130 (1,100) PENCE - 'BUY'
----------
UBS CUTS COCA-COLA HBC TARGET TO 1,360 (1,450) PENCE - 'NEUTRAL'
----------
Nomura Cuts Coca-Cola HBC Price Target To 1,100p From 1,140p, Maintains Reduce
----------
UBS CUTS RSA INSURANCE PRICE TARGET TO 418 (427) PENCE - 'SELL'
----------
EXANE BNP RAISES RSA INSURANCE PRICE TARGET TO 430 (405) PENCE - 'UNDERPERFORM'
----------
UBS RAISES SCHRODERS PRICE TARGET TO 2,800 (2,400) PENCE - 'NEUTRAL'
----------
BERENBERG CUTS GLAXOSMITHKLINE PRICE TARGET TO 1540 (1575) PENCE - 'HOLD'
----------
CITIGROUP RAISES 3I GROUP PRICE TARGET TO 455 (430) PENCE - 'BUY'
----------
S&P CAPITAL IQ CUTS MORRISON TO 'SELL' ('HOLD') - TARGET 155 (195) PENCE
----------
LBBW RAISES ASTRAZENECA PRICE TARGET TO 3900 (3600) PENCE - 'SELL'
----------
NUMIS CUTS HSBC PRICE TARGET TO 700 (725) PENCE - 'ADD'
----------
NUMIS CUTS RANDGOLD RESOURCES PRICE TARGET TO 4,900 (5,100) PENCE - 'BUY'
----------
S&P CAPITAL IQ RAISES ASTRAZENECA PRICE TARGET TO 4700 (4500) PENCE - 'HOLD'
----------
FTSE 250
----------
GOLDMAN CUTS HAYS PRICE TARGET TO 153 (185) PENCE - 'BUY'
----------
TRADERS: GOLDMAN REMOVES HAYS FROM 'CONVICTION BUY LIST' - STILL 'BUY'
----------
GOLDMAN RAISES FIRSTGROUP PRICE TARGET TO 165 (160) PENCE - 'NEUTRAL'
----------
GOLDMAN RAISES BERENDSEN PRICE TARGET TO 1170 (1132) PENCE - 'NEUTRAL'
----------
GOLDMAN CUTS MICHAEL PAGE TO 'NEUTRAL' ('BUY') - TARGET 467 (570) PENCE
----------
GOLDMAN CUTS HIKMA PHARMA TO 'NEUTRAL' ('BUY') - TARGET 2120 (2250) PENCE
----------
MORGAN STANLEY RAISES WILLIAM HILL TARGET TO 460 (425) PENCE - 'OVERWEIGHT'
----------
TRADERS: SOCGEN CUTS AVEVA GROUP PRICE TARGET TO 2000 (2250) PENCE - 'BUY'
----------
CHARLES STANLEY RAISES COBHAM TO 'HOLD' ('REDUCE')
----------
BARCLAYS CUTS LONMIN PRICE TARGET TO 190 (205) PENCE - 'UNDERWEIGHT'
----------
BARCLAYS CUTS HALFORDS GROUP PRICE TARGET TO 385 (400) PENCE - 'UNDERWEIGHT'
----------
BARCLAYS CUTS LANCASHIRE HLDGS PRICE TARGET TO 494 (575) PENCE - 'UNDERWEIGHT'
----------
BARCLAYS INITIATES INFINIS ENERGY WITH 'OVERWEIGHT' - TARGET 275 PENCE
----------
TRADERS: JPMORGAN RAISES CRODA PRICE TARGET TO 2,300 (2,250) PENCE - 'NEUTRAL'
----------
HSBC CUTS JD WETHERSPOON PRICE TARGET TO 820 (850) PENCE - 'NEUTRAL'
----------
EXANE BNP CUTS TATE & LYLE PRICE TARGET TO 600 (610) PENCE - 'NEUTRAL'
----------
CITIGROUP RAISES BIG YELLOW GROUP PRICE TARGET TO 540 (470) PENCE - 'NEUTRAL'
----------
CITIGROUP CUTS UBM PRICE TARGET TO 670 (820) PENCE - 'BUY'
----------
CITIGROUP INITIATES POUNDLAND GROUP WITH 'BUY' - TARGET 350 PENCE
----------
TRADERS: JPMORGAN CUTS PLAYTECH TO 'NEUTRAL' ('OVERWEIGHT') - TARGET 615 (860) PENCE
----------
MAIN MARKET AND AIM
----------
CITIGROUP INITIATES B&M WITH 'BUY' - TARGET 310 PENCE
----------
PANMURE RAISES LOOKERS PRICE TARGET TO 175 (166) PENCE - 'BUY'
----------
PANMURE RAISES FILTRONIC PRICE TARGET TO 23 (20) PENCE - 'HOLD'
----------
TRADERS: JPMORGAN CUTS PROMETHEAN TO 'UNDERWEIGHT' ('NEUTRAL')
----------
TRADERS: JPMORGAN RAISES GEM DIAMONDS TARGET TO 280 (270) P - 'OVERWEIGHT'
----------
Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
13 Feb 2024 16:21

London close: Stocks fall as US inflation tops expectations

(Sharecast News) - London markets ended the trading day in negative territory on Tuesday, influenced by concerns over higher inflation figures from the United States and a deceleration in wage growth within the UK.

Read more
13 Feb 2024 16:21

London close: Stocks fall as US inflation tops expectations

(Sharecast News) - London markets ended the trading day in negative territory on Tuesday, influenced by concerns over higher inflation figures from the United States and a deceleration in wage growth within the UK.

Read more
13 Feb 2024 12:06

LONDON MARKET MIDDAY: Stocks fall but pound up before US data

(Alliance News) - Stock prices in London were on the decline on Tuesday afternoon, with sentiment tetchy ahead of a US inflation report later.

Read more
13 Feb 2024 09:45

Citi ups recommendation on GSK to 'buy'

(Sharecast News) - Citi has upgraded its rating on vaccines and drugs blue chip GSK to 'buy' while also boosting its earnings estimates.

Read more
13 Feb 2024 09:32

LONDON BROKER RATINGS: Citi lifts GSK; Shore likes XPS Pensions

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
13 Feb 2024 07:45

LONDON BRIEFING: "Record" Tui quarter; Ultimate Products eyes payouts

(Alliance News) - London's FTSE 100 is to open ever-so-slightly lower on Tuesday, with trade set to be nervy ahead of the afternoon's US inflation data.

Read more
12 Feb 2024 17:11

London close: Stocks finish higher after very quiet Monday

(Sharecast News) - London markets managed modest gains by the close of a subdued trading session on Monday, with no significant corporate or economic catalysts driving movements.

Read more
12 Feb 2024 12:04

LONDON MARKET MIDDAY: FTSE 100 underperforms as European peers rise

(Alliance News) - London's FTSE 100 underwhelmed on Monday, with some of its largest constituents pulling it lower, while indices in Europe were on the up on favourable comments on interest rate cuts by a European Central Bank official.

Read more
12 Feb 2024 08:35

TOP NEWS: GSK's bepirovirsen receives US FDA fast track designation

(Alliance News) - GSK PLC on Monday said that the US health watchdog granted fast track designation for its bepirovirsen treatment for chronic hepatitis B.

Read more
12 Feb 2024 07:50

LONDON BRIEFING: Tritax Big Box, UK Commercial Property agree merger

(Alliance News) - Equities in London are called to open higher on Monday, with inflation readings from the US and UK on the horizon, which could drive equity market sentiment during the remainder of the week.

Read more
12 Feb 2024 07:21

GSK gets FDA fast track for chronic hepatitis B treatment

(Sharecast News) - GSK announced on Monday that bepirovirsen, an investigational antisense oligonucleotide (ASO) aimed at treating chronic hepatitis B (CHB), had been granted fast track designation by the US Food and Drug Administration (FDA).

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
6 Feb 2024 08:51

TOP NEWS: GSK reports positive news on trio of high profile products

(Alliance News) - GSK PLC on Tuesday delivered a triple dose of positive updates on some of its leading products, Arexvy, Shingrix and Blencep.

Read more
6 Feb 2024 07:47

LONDON BRIEFING: BP promises buyback despite drop in profit

(Alliance News) - Stocks in London are called to open higher, ahead of a slew of construction purchasing managers' index readings from the eurozone, the UK and Germany.

Read more
6 Feb 2024 07:23

GSK reports positive myeloma trial results, progresses vaccine applications

(Sharecast News) - GSK reported progress in its trial of a myeloma treatment on Tuesday, as well as regulatory progress around its shingles vaccine in China and its RSV vaccine in the United States.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.